tiprankstipranks
Trending News
More News >
Nu Skin Enterprises (NUS)
:NUS
Advertisement

Nu Skin (NUS) AI Stock Analysis

Compare
467 Followers

Top Page

NUS

Nu Skin

(NYSE:NUS)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
$11.50
▲(6.48% Upside)
Nu Skin's overall stock score reflects a mix of strengths and challenges. The positive earnings call and attractive valuation are significant positives, while financial performance and technical indicators present concerns. The company's ability to manage costs and innovate, as seen with Prysm iO, provides a positive outlook despite regional challenges.
Positive Factors
Strong Latin America Growth
The significant growth in Latin America highlights the effectiveness of Nu Skin's business model in emerging markets, providing a strong foundation for future expansion and revenue diversification.
Innovation with Prysm iO
Prysm iO represents a structural innovation that could enhance customer engagement and product personalization, potentially driving long-term growth and competitive advantage.
Improved Debt Position
Achieving a net cash positive position enhances Nu Skin's financial flexibility, allowing for strategic investments and reducing financial risk over the long term.
Negative Factors
Declining Revenue Growth
The negative revenue growth trend indicates challenges in maintaining market share and sales momentum, which could impact long-term profitability and market position.
Challenges in North America
Macroeconomic pressures in North America could lead to sustained challenges in this key market, potentially affecting overall revenue and growth prospects.
Declining Cash Flow
The decline in free cash flow suggests reduced cash generation ability, which may limit Nu Skin's capacity to invest in growth initiatives and manage financial obligations effectively.

Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)

Nu Skin Business Overview & Revenue Model

Company DescriptionNu Skin Enterprises, Inc. (NUS) is a global health and wellness company that develops and distributes personal care products and dietary supplements. Founded in 1984 and headquartered in Provo, Utah, Nu Skin operates in the direct selling sector, offering a range of products including skincare, anti-aging, and nutritional supplements. The company markets its products through a network of independent distributors, leveraging a multi-level marketing (MLM) model to reach consumers worldwide.
How the Company Makes MoneyNu Skin generates revenue primarily through the sale of its products to consumers via its network of independent distributors. The company employs a multi-level marketing (MLM) strategy, which allows distributors to earn commissions not only on their sales but also on the sales made by their recruits. This creates a tiered earning structure that incentivizes recruitment and sales. Key revenue streams include skincare and beauty products, dietary supplements, and personal care items, with a significant portion of sales originating from markets in Asia and North America. Partnerships with various health and wellness organizations, as well as investments in product innovation and technology, further enhance Nu Skin's market presence and contribute to its overall earnings.

Nu Skin Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance with revenue and earnings surpassing expectations, significant growth in Latin America, and successful cost management initiatives. However, challenges remain in North America and the Asian markets, with some decline in gross margin. The overall sentiment is bolstered by promising innovations like Prysm iO and financial stability, resulting in a positive outlook.
Q2-2025 Updates
Positive Updates
Revenue and Earnings Exceed Expectations
Nu Skin delivered revenue of $386.1 million, at the high end of its guidance range, and significantly exceeded its earnings per share forecast with $0.43, above the guidance range of $0.20 to $0.30, showcasing strong cost management and operational efficiency.
Latin America Market Success
Latin America demonstrated remarkable performance with more than 100% year-over-year growth in revenue, customers, and sales leaders, driven by a simplified and focused business model.
Project Accelerate and Margin Expansion
Project Accelerate led to an operating margin increase to 8%, driven by improvements in gross margin, selling expense alignment, and G&A cost reductions.
Positive Cash Flow and Debt Position
The company generated $35.8 million in cash flow from operations, achieving a net cash positive position for the first time in over four years, providing greater financial flexibility.
Rhyz Segment and Manufacturing Growth
Rhyz segments performed well, with manufacturing reporting a 17% year-over-year increase, contributing to speed to market for new products.
Innovation with Prysm iO
The introduction of Prysm iO, an intelligent wellness platform leveraging AI and a vast antioxidant database, is expected to bring personalized health insights and product recommendations to consumers.
Negative Updates
Declines in North America
North America faced increasing macroeconomic pressures, which negatively impacted the business performance in the region.
Economic Challenges in South Korea and China
Revenue in South Korea and China declined due to persistent economic challenges, although there are signs of sequential improvement.
Gross Margin Decline
The Q2 gross margin was 68.8%, down from 70% in the prior year, primarily due to changes in revenue mix following the sale of Mavely.
Company Guidance
In the Q2 2025 Nu Skin Enterprises earnings call, the company reported revenue of $386.1 million, reaching the high end of their guidance range, and an earnings per share (EPS) of $0.43, significantly exceeding the forecasted range of $0.20 to $0.30. This was attributed to disciplined cost management and operational efficiencies. The company highlighted strong growth in Latin America with over 100% year-over-year revenue increase, while North America experienced declines due to macroeconomic pressures. Japan showed growth, benefiting from a strong subscription-based wellness business, although revenue in South Korea and China declined. Nu Skin announced plans to launch their new wellness platform, Prysm iO, globally in 2026, and reported a 17% year-over-year growth in their Rhyz manufacturing segment. The company aims to improve gross margins to 78% and anticipates a net cash-positive position, enhancing flexibility for future investments. Guidance for Q3 2025 projects revenue between $360 million and $390 million, with EPS expected to range from $0.25 to $0.35.

Nu Skin Financial Statement Overview

Summary
Nu Skin is facing financial headwinds with declining revenues and profitability impacting both its income statement and balance sheet. While cash flow remains positive, the company needs to improve operational efficiency and profitability to strengthen its financial position. The balance sheet is moderately leveraged, providing some financial stability, but the company must focus on reversing its negative profitability trend.
Income Statement
65
Positive
Nu Skin has experienced declining revenue and profitability over the recent periods. The TTM revenue is down from previous years, and net income has turned negative. Gross profit margin remains relatively stable, but the net profit margin has deteriorated due to negative EBIT and EBITDA. The company needs to address its operational inefficiencies to return to profitability.
Balance Sheet
70
Positive
The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the decline in stockholders' equity and total assets is concerning. Return on equity has turned negative, reflecting poor profitability. The equity ratio remains stable, suggesting a decent level of financial stability despite recent challenges.
Cash Flow
60
Neutral
Nu Skin's cash flow situation is relatively stable, with positive free cash flow and operating cash flow. However, the growth in free cash flow is limited, and the company has faced challenges in translating its cash flow into net income. Continued positive cash flow is a positive sign, but improvements in profitability are needed for long-term stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.63B1.73B1.97B2.23B2.70B2.58B
Gross Profit1.09B1.18B1.36B1.62B2.02B1.92B
EBITDA196.71M-78.83M202.98M231.85M368.48M331.56M
Net Income100.83M-146.59M8.60M104.78M147.27M191.35M
Balance Sheet
Total Assets1.44B1.47B1.81B1.82B1.91B1.96B
Cash, Cash Equivalents and Short-Term Investments264.16M197.99M267.82M278.51M354.81M423.90M
Total Debt310.74M478.23M607.33M520.52M503.79M500.38M
Total Liabilities655.94M817.46M984.50M923.67M993.71M1.06B
Stockholders Equity787.75M651.46M821.97M897.30M912.77M894.27M
Cash Flow
Free Cash Flow58.62M70.16M60.15M49.01M72.97M315.32M
Operating Cash Flow93.40M111.74M118.64M108.06M141.58M379.14M
Investing Cash Flow170.17M-37.96M-134.50M-67.08M-88.73M-79.43M
Financing Cash Flow-229.43M-133.18M10.73M-99.50M-104.70M-245.17M

Nu Skin Technical Analysis

Technical Analysis Sentiment
Negative
Last Price10.80
Price Trends
50DMA
11.52
Negative
100DMA
10.21
Positive
200DMA
8.59
Positive
Market Momentum
MACD
-0.20
Negative
RSI
39.88
Neutral
STOCH
22.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 10.8 is below the 20-day moving average (MA) of 10.85, below the 50-day MA of 11.52, and above the 200-day MA of 8.59, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 39.88 is Neutral, neither overbought nor oversold. The STOCH value of 22.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.

Nu Skin Risk Analysis

Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Nu Skin Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$6.98B73.0212.97%18.61%-21.36%
$527.15M5.3613.68%2.25%-11.79%
$880.96M14.504.12%3.11%-2.92%-43.06%
$20.33B14.63-3.31%3.23%1.93%-12.26%
$35.13B-24.69%1.43%-8.14%-389.12%
$3.43B-9.98%-3.68%-631.67%
$176.29M-4.94-26.54%-15.33%75.52%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NUS
Nu Skin
10.62
4.46
72.40%
EL
The Estée Lauder Companies
97.61
32.25
49.34%
COTY
Coty
3.93
-3.55
-47.46%
EPC
Edgewell Personal Care
19.32
-15.03
-43.76%
ELF
e.l.f. Beauty
123.11
19.99
19.39%
SKIN
Beauty Health
1.41
-0.25
-15.06%

Nu Skin Corporate Events

Nu Skin’s Innovative Study on Skin Health: A Market Game-Changer?
Sep 30, 2025

Nu Skin Enterprises, in collaboration with ChinaNorm, is conducting a study titled Study on Carotenoid-Based Instrumental Index. The primary objective is to evaluate the effectiveness of a new biophotonic scanner, the Prysm device, in measuring skin carotenoid levels and analyzing their correlation with dietary and lifestyle factors. This study holds significance for understanding how lifestyle choices impact skin health.

Nu Skin Enterprises Surpasses Earnings Expectations Amid Challenges
Aug 12, 2025

Nu Skin Enterprises recently held its earnings call, revealing a blend of positive achievements and ongoing challenges. The company surpassed earnings expectations, demonstrating strong growth in Latin America and improvements in operational efficiency. However, it faces hurdles with declining revenues in North America and economic difficulties in China and South Korea. Despite these obstacles, the overall sentiment remains cautiously optimistic, driven by strategic plans and performance metrics.

Nu Skin Enterprises Reports Strong Q2 2025 Results
Aug 8, 2025

Nu Skin Enterprises Inc. is an integrated beauty and wellness company that operates globally, offering personal care, nutrition, and anti-aging products through a dynamic affiliate platform.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025